	US 11,883,376 B2
	Viral infection treatment with 5-aminolevulinic acid
Nadimpally Satyavarahala Raju, Hyderabad (IN); Venkata Satya Suresh Attili, Hyderabad (IN); Nadimpally Neha Varma, Hyderabad (IN); Steven Jerome Moore, Newtown, CT (US); and Cullen Thomas Moore, Newtown, CT (US)
Filed by Nadimpally Satyavarahala Raju, Hyderabad (IN); Venkata Satya Suresh Attili, Hyderabad (IN); Nadimpally Neha Varma, Hyderabad (IN); Steven Jerome Moore, Newtown, CT (US); and Cullen Thomas Moore, Newtown, CT (US)
Filed on Jun. 6, 2021, as Appl. No. 17/340,064.
Application 17/340,064 is a division of application No. 16/920,000, filed on Jul. 2, 2020, granted, now 10,987,329, issued on Apr. 27, 2021.
Claims priority of application No. 2020/41017237 (IN), filed on Apr. 22, 2020; and application No. 2020/41026186 (IN), filed on Jun. 4, 2020.
Prior Publication US 2021/0330622 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/197 (2006.01); A61K 36/23 (2006.01); A61K 31/375 (2006.01); A61K 31/315 (2006.01)

CPC A61K 31/197 (2013.01) [A61K 31/315 (2013.01); A61K 31/375 (2013.01); A61K 36/23 (2013.01)]

10 Claims

1. A method for amelioriation of a viral infection comprising administering to a patient in need of treatment a therapeutically effective amount of 5-aminolevulinic acid, or pharmaceutically acceptable salt thereof.